Increased plasma concentrations of total homocysteine (tHcy; mild-moderate hyperhomocysteinemia: 15–50 μM tHcy) are considered an independent risk factor for the onset/progression of various diseases, but it is not known about how the increase in tHcy causes pathological conditions.
Recent Advances:
Reduced homocysteine (HSH ∼1% of tHcy) is presumed to be toxic, unlike homocystine (∼9%) and mixed disulfide between homocysteine and albumin (HSS-ALB; homocysteine [Hcy]-albumin mixed disulfide, ∼90%). This and other notions make it difficult to explain the pathogenicity of Hcy because: (i) lowering tHcy does not improve pathological outcomes; (ii) damage due to HSH usually emerges at supraphysiological doses; and (iii) it is not known why tiny increments in plasma concentrations of HSH can be pathological.
Critical Issues:
Albumin may have a role in Hcy toxicity, because HSS-ALB could release toxic HSH via thiol-disulfide (SH/SS) exchange reactions in cells. Similarly, thiol-disulfide exchange processes of reduced albumin (albumin with free SH group of Cys34 [HS-ALB]) or N-homocysteinylated albumin are plausible alternatives for initiating Hcy pathological events. Adverse effects of albumin and other data reviewed here suggest the hypothesis of a role of albumin in Hcy toxicity.
Future Directions:
HSS-ALB might be involved in disruption of the antioxidant/oxidant balance in critical tissues (brain, liver, kidney). Since homocysteine-albumin mixed disulfide is a possible intermediate of thiol-disulfide exchange reactions, we suggest that homocysteinylated albumin could be a new pathological factor, and that studies on the redox role of albumin and mixed disulfide production via thiol-disulfide exchange reactions could offer new therapeutic insights for reducing Hcy toxicity.
Get full access to this article
View all access options for this article.
References
1.
AbbottN, AbbottJ, RönnbäckL, and HanssonE. Astrocyte–endothelial interactions at the blood–brain barrier. Nat Rev Neurosci, 7: 41–45, 2006.
2.
AbbottNJ, PatabendigeAA, DolmanDE, YusofSR, and BegleyDJ. Structure and function of the blood-brain barrier. Neurobiol Dis, 37: 13–25, 2010.
3.
AboM and WeerapanaE. A caged electrophilic probe for global analysis of cysteine reactivity in living cells. J Am Chem Soc, 137: 7087–7090, 2015.
4.
AhalawatN and MurarkaRK. Conformational changes and allosteric communications in human serum albumin due to ligand binding. J Biomol Struct Dyn, 33: 2192–2204, 2015.
5.
AhnSM, ByunK, ChoK, KimJY, YooJS, KimD, PaekSH, KimSU, SimpsonRJ, and LeeB. Human microglial cells synthesize albumin in brain. PLoS ONE, 3: e2829, 2008.
6.
AmsellemS, GburekJ, HamardG, NielsenR, WillnowTE, DevuystO, NexoE, VerroustPJ, ChristensenEI, and KozyrakiR. Cubilin is essential for albumin reabsorption in the renal proximal tubule. J Am Soc Nephrol, 21: 1859–1867, 2010.
7.
AndersenJT, DalhusB, CameronJ, DabaMB, PlumridgeA, EvansL, BrennanSO, GunnarsenKS, BjøråsM, SleepD, and SandlieI. Structure-based mutagenesis reveals the albumin-binding site of the neonatal Fc receptor. Nat Commun, 3: 610, 2012.
8.
AndersenJT, DalhusB, ViuffD, RavnBT, GunnarsenKS, PlumridgeA, BuntingK, AntunesF, WilliamsonR, AthwalS, AllanE, EvansL, BjøråsM, KjærulffS, SleepD, SandlieI, and CameronJ. Extending serum half-life of albumin by engineering neonatal Fc receptor (FcRn) binding. J Biol Chem, 289: 13492–13502, 2014.
9.
AndersenJT, Dee QianJ, and SandlieI. The conserved histidine 166 residue of the human neonatal Fc receptor heavy chain is critical for the pH-dependent binding to albumin. Eur J Immunol, 36: 3044–3051, 2006.
10.
AndersonC, ChaudhuryC, KimJ, BronsonC, WaniM, and MohantyS. Perspective–FcRn transports albumin: relevance to immunology and medicine. Trends Immunol, 27: 343–348, 2006.
11.
AnguizolaJA, BasiagaSB, and HageDS. Effects of fatty acids and glycation on drug interactions with human serum albumin. Curr Metabolomics, 1: 239–250, 2013.
12.
AscenziP, BocediA, NotariS, FanaliG, FesceR, and FasanoM. Allosteric modulation of drug binding to human serum albumin. Mini Rev Med Chem, 6: 483–489, 2006.
13.
AscenziP and FasanoM. Allostery in a monomeric protein: the case of human serum albumin. Biophys Chem, 148: 16–22, 2010.
14.
AseemO, SmithBT, CooleyMA, WilkersonBA, ArgravesKM, RemaleyAT, and ArgravesWS. Cubilin maintains blood levels of HDL and albumin. J Am Soc Nephrol, 25: 1028–1036, 2014.
15.
AshbrookJD, SpectorAA, SantosEC, and FletcherJE. Long chain fatty acid binding to human plasma albumin. J Biol Chem, 250: 2333–2338, 1975.
16.
AtaieA, AtaeeR, Zahra MansouryZ, and AghajanpourM. Homocysteine intracerebroventricular injection induces apoptosis in the substantia nigra cells and Parkinson's disease like behavior in rats. Int J Mol Cell Med, 2: 80–85, 2013.
17.
AthyrosVG, TziomalosK, KaragiannisA, and MikhailidisDP. Homocysteine: an emerging cardiovascular risk factor that never really made it. Open Clin Chem J, 3: 19–24, 2010.
18.
AustinRC, LentzSR, and WerstuckGH. Role of hyperhomocysteinemia in endothelial dysfunction and atherothrombotic disease. Cell Death Differ, 11: S56–S64, 2004.
19.
BaggottJE and TamurT. Homocysteine, iron and cardiovascular disease: a hypothesis. Nutrients, 7: 1108–1118, 2015.
20.
BaldessariniRJ. Alterations in tissue levels of S-adenosylmethionine. Biochem Pharmacol, 15: 741–748, 1966.
21.
BallatoriN, KranceSM, MarchanR, and HammondCL. Plasma membrane glutathione transporters and their roles in cell physiology and pathophysiology. Mol Aspects Med, 30: 13–28, 2009.
22.
BandarianV, PattridgeKA, LennonBW, HuddlerDP, MatthewsRG, and LudwigML. Domain alternation switches B(12)-dependent methionine synthase to the activation conformation. Nat Struct Biol, 9: 53–56, 2002.
23.
BanerjeeR. B12 trafficking in mammals: a case for coenzyme escort service. ACS Chem Biol, 1: 149–159, 2006.
24.
BanerjeeR and ZouCG. Redox regulation and reaction mechanism of human cystathionine-beta-synthase: a PLP-dependent hemesensor protein. Arch Biochem Biophys, 433: 144–156, 2005.
25.
BannaiS. Transport of cystine and cysteine in mammalian cells. Biochim Biophys Acta, 779: 289–306, 1984.
26.
BarnettJP, BlindauerCA, KassaarO, KhazaipoulS, MartinEM, SadlerPJ, and StewartAJ. Allosteric modulation of zinc speciation by fatty acids. Biochim Biophys Acta, 1830: 5456–5464, 2013.
27.
BarrosoM, HandyDE, and CastroR. The link between hyperhomocysteinemia and hypomethylation: implications for cardiovascular disease. J Inborn Errors Metab Screen, 5: 1–15, 2017.
28.
BarthJL and ArgravesWS. Cubilin and megalin: partners in lipoprotein and vitamin metabolism. Trends Cardiovasc Med, 11: 26–31, 2001.
29.
BaskenNE, MathiasCJ, and GreenMA. Elucidation of the human serum albumin (HSA) binding site for the Cu-PTSM andCu-ATSM. radiopharmaceuticals. J Pharm Sci, 98: 2170–2179, 2009.
30.
BaumanA and RothschildMA. The rate of intravascular equilibration of intravenously administered JI31 labeled albumin in various body sites. J Lab Clin Med, 48: 20–25, 1956.
31.
BaumannN and Pham-DinhD. Biology of oligodendrocyte and myelin in the mammalian central nervous system. Physiol Rev, 81: 871–927, 2001.
32.
BelinskaiaDA, VoroninaPA, ShmurakVI, VovkMA, BatalovaAA, JenkinsRO, and GoncharovNV. The universal soldier: enzymatic and non-enzymatic antioxidant functions of serum albumin. Antioxidants (Basel), 9: 966, 2020.
33.
Bhakthavatsala ReddyC, CyriacC, and DesleHB. Role of “ischemia modified albumin” (IMA) in acute coronary syndromes. Indian Heart J, 66: 656–662, 2014.
34.
BhattacharyaAA, GrüneT, and CurryS. Crystallographic analysis reveals common modes of binding of medium and long-chain fatty acids to human serum albumin. J Mol Biol, 303: 721–732, 2000.
35.
BirnH. The kidney in vitamin B12 and folate homeostasis: characterization of receptors for tubular uptake of vitamins and carrier proteins. Am J Physiol Renal Physiol, 291: F22–F36, 2006.
36.
BirnH and ChristensenEI. Renal albumin absorption in physiology and pathology. Kidney Int, 69: 440–449, 2006.
37.
BlomHJ and De VrieseS. Why are homocysteine levels increased in kidney failure?A metabolic. approach. J Lab Clin Med, 139: 262–268, 2002.
38.
BlumbergRS, KossT, StoryCM, BarisaniD, PolischukJ, LipinA, PabloL, GreenR, and SimisterNE. A major histocompatibility complex class I-related Fc receptor for IgG on rat hepatocytes. J Clin Invest, 95: 2397–2402, 1995.
BottiglieriT, LaundyM, CrellinR, TooneBK, CarneyMW, and ReynoldsEH. Homocysteine, folate, methylation, and monoamine metabolism in depression. J Neurol Neurosurg Psychiatry, 69: 228–232, 2000.
41.
BousheyCJ, BeresfordSA, OmennGS, and MotulskyAG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA, 274: 1049–1057, 1995.
42.
BrinkkoetterPT, IsingC, and BenzingT. The role of the podocyte in albumin filtration. Nat Rev Nephrol, 9: 328–336, 2013.
CantoniGL. The role of S-adenosylhomocysteine in the biological utilization of S-adenosylmethionine. Prog Clin Biol Res, 198: 47–65, 1985.
46.
CaplanMJ. Ion pump sorting in polarized renal epithelial cells. Kidney Int, 60: 427–430, 2001.
47.
CarballalS, AlvarezB, TurellL, BottiH, FreemanBA, and RadiR. Sulfenic acid in human serum albumin. Amino Acids, 32: 543–551, 2007.
48.
CarterDC and HoJX. Structure of serum albumin. Adv Protein Chem, 45: 153–203, 1994.
49.
ChaMK and KimI-H. Disulfide between Cys392 and Cys438 of human serum albumin is redox-active, which is responsible for the thioredoxin-supported lipid peroxidase activity. Arch Biochem Biophys, 445: 19–25, 2006.
50.
ChambersJC, UelandPM, WrightM, DoréCJ, RefsumH, and KoonerJS. Investigation of relationship between reduced, oxidized, and protein-bound homocysteine and vascular endothelial function in healthy human subjects. Circ Res, 89: 187–192, 2001.
51.
ChaudhuryC, BrooksCL, CarterDC, RobinsonJM, and AndersonCL. Albumin binding to FcRn: distinct from theFcRn-IgG. interaction. Biochemistry, 45: 4983–4990, 2006.
52.
ChaudhuryC, MehnazS, RobinsonJM, HaytonWL, PearlDK, RoopenianDC, and AndersonCL. The major histocompatibility complex-related Fc receptor for IgG (FcRn) binds albumin and prolongs its lifespan. J Exp Med, 197: 315–322, 2003.
53.
ChauveauP, ChadefauxB, CoúdeM, AupetitJ, HannedoucheT, KamounP, and JungersP. Hyperhomocysteinemia, a risk factor for atherosclerosis in chronic uremic patients. Kidney Int Suppl, 41: S72–S77, 1993.
54.
ChoudhuryS and BorahA. Activation of NMDA receptor by elevated homocysteine in chronic liver disease contributes to encephalopathy. Med Hypotheses, 85: 64–67, 2015.
55.
ChristensenEI and BirnH. Megalin and cubilin: multifunctional endocytic receptors. Nat Rev Mol Cell Biol, 3: 256–266, 2002.
56.
ChristensenEI, BirnH, StormT, WeyerK, and NielsenR. Endocytic receptors in the renal proximal tubule. Physiology, 27: 223–236, 2012.
57.
ChristodoulouJ, SadlerPJ, and TuckerA. 1H NMR of albumin in human blood plasma: drug binding and redox reactions at Cys34. FEBS Lett, 376: 1–5, 1995.
58.
ChuangVT and OtagiriM. How do fatty acids cause allosteric binding of drugs to human serum albumin?. Pharm Res, 19: 1458–1464, 2002.
59.
CommissoC, DavidsonSM, Soydaner-AzelogluRG, ParkerSJ, KamphorstJJ, HackettS, GrabockaE, NofalM, DrebinJA, ThompsonCB, RabinowitzJD, MetalloCM, Vander HeidenMG, and Bar-SagiD. Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells. Nature, 497: 633–637, 2013.
60.
CompstonA and ColesA. Multiple sclerosis. Lancet, 372: 1502–1517, 2008.
61.
ConwayEM, NowakowskiB, and Steiner-MosonyiM. Thrombomodulin lacking the cytoplasmic domain efficiently internalizes thrombin via nonclathrin-coated, pit-mediated endocytosis. J Cell Physiol, 158: 285–298, 1994.
62.
CoppackSW, JensenMD, and MilesJM. In vivo regulation of lipolysis in humans. J Lipid Res, 35: 177–193, 1994.
63.
CorralesFJ, RuizF, and MatoJM. In vivo regulation by glutathione of methionine adenosyltransferase S-nitrosylation in rat liver. J Hepatol, 31: 887–894, 1999.
64.
CurryS. Lessons from the crystallographic analysis of small molecule binding to human serum albumin. Drug Metab Pharmacokinet, 24: 342–357, 2009.
65.
CurryS, BrickP, and FranksNP. Fatty acid binding to human serum albumin: new insights from crystallographic studies. Biochim Biophys Acta, 144: 1131–1140, 1999.
66.
CurryS, MandelkowH, BrickP, and FranksN. Crystal structure of human serum albumin complexed with fatty acid reveals an asymmetric distribution of binding sites. Nat Struct Biol, 5: 827–835, 1998.
67.
CutlerMJ, UrquhartBL, FreemanDJ, SpenceJD, and HouseAA. Mesna for the treatment of hyperhomocysteinemia in hemodialysis patients. Blood Purif, 27: 306–310, 2009.
68.
da CunhaMJ, da CunhaAA, FerreiraAGK, MachadoFR, SchmitzF, LimaDD, DelwingD, MussuliniBHM, WofchukS, NettoCA, and WyseATS. Physical exercise reverses glutamate uptake and oxidative stress effects of chronic homocysteine administration in the rat. Int J Dev Neurosci, 30: 69–74, 2012.
69.
DasguptaA and CrosseyMJ. Elevated free fatty acid concentrations in lipemic sera reduce protein binding of valproic acid significantly more than phenytoin. Am J Med Sci, 313: 75–79, 1997.
70.
DayalS, ArningE, BottiglieriT, BögerRH, SigmundCD, FaraciFM, and LentzSR. Cerebral vascular dysfunction mediated by superoxide in hyperhomocysteinemic mice. Stroke, 35: 1957–1962, 2004.
71.
de Sá FerreiraA. Plasma homocysteine and arterial stiffness: Risk factors or risk markers for cardiovascular diseases?. J Clin Hypertens (Greenwich), 17: 601–602, 2015.
72.
DeberCM, BrodskyB, and RathA. Proline Residues in Proteins. In: eLS. Chichester: John Wiley & Sons Ltd., 2010.
73.
den HeijerM, LewingtonS, and ClarkeR. HomocysteineMTHFR and risk of venous thrombosis: a meta-analysis of published epidemiological studies. J Thromb Haemost, 3: 292–299, 2005.
74.
den HeijerT, VermeerSE, ClarkeR, OudkerkM, KoudstaalPJ, HofmanA, and BretelerMM. Homocysteine and brain atrophy on MRI of non-demented elderly. Brain, 126: 170–175, 2003.
75.
Devarie-BaezNO, Silva LopezEI, and FurduiCM. Biological chemistry and functionality of protein sulfenic acids and related thiol modifications. Free Radic Res, 50: 172–194, 2016.
76.
Di GiuseppeD, FrosaliS, PrioraR, Cherubini Di SimplicioF, BuonocoreG, CellesiC, CapecchiPL, Laghi PasiniF, LazzeriniPE, JakubowskiH, and Di SimplicioP. The effect of age and hyperhomocysteinemia on the redox forms of plasma thiols. J Lab Clin Med, 144: 235–245, 2004.
77.
Di GiuseppeD, PrioraR, CoppoL, UlivelliM, BartaliniS, SummaD, MargaritisA, FrosaliS, and Di SimplicioP. The control of hyperhomocysteinemia through thiol exchange mechanisms by mesna. Amino Acids, 46: 429–439, 2014.
78.
Di GiuseppeD, UlivelliM, BartaliniS, BattistiniS, CeraseA, PasseroS, SummaD, FrosaliS, PrioraR, MargaritisA, and Di SimplicioP. Regulation of redox forms of plasma thiols by albumin in multiple sclerosis after fasting and methionine loading test. Amino Acids, 38: 1461–1471, 2010.
79.
Di SimplicioP. An improved method of determination of SH group concentration and reactivity in plasma of patients with various clinical disorders and in rats after administration of indomethacin or carbon tetrachloride. Pharmacol Res Commun, 15: 805–814, 1983.
80.
Di SimplicioP, CacaceM, LusiniL, GianneriniF, GiustariniD, and RossiR. Role of protein-SH groups in redox homeostasis—the erythrocytes as a model system. Arch Biochem Biophys, 355: 145–152, 1998a.
81.
Di SimplicioP, FranconiF, FrosaliS, and Di GiuseppeD. Thiolation and nitrosation of cysteines in biological fluids and cells. Amino Acids, 25: 323–339, 2003.
82.
Di SimplicioP, FrosaliS, PrioraR, SummaD, Cherubini Di SimplicioF, Di GiuseppeD, and Di StefanoA. Biochemical and biological aspects of protein thiolation in cells and plasma. Antioxid Redox Signal, 7: 951–963, 2005.
83.
Di SimplicioP, GianneriniF, GiustariniD, LusiniL, and RossiR. The role of cysteine in the regulation of blood glutathione–protein mixed disulfides in rats treated with diamide. Toxicol Appl Pharmacol, 148: 56–64, 1998b.
84.
Di SimplicioP, LupisE, and RossiR. Different mechanisms of formation of glutathione-protein mixed disulfides of diamide andt-butyl hydroperoxide in rat blood. Biochim Biophys Acta, 1289: 252–260, 1996.
85.
DixonRJ, YoungK, and BrunskillNJ. Lysophosphatidic acid-induced calcium mobilization and proliferation in kidney proximal tubular cells. Am J Physiol, 276: F191–F198, 1999.
86.
DobrinskikhE, OkamuraK, KoppJB, DoctorRB, and BlaineJ. Human podocytes perform polarized, caveolae-dependent albumin endocytosis. Am J Physiol Renal Physiol, 306: F941–F951, 2014.
87.
DongF, ZhangX, LiS-Y, ZhangZ, RenQ, CulverB, and RenJ. Possible involvement of NADPH oxidase and JNK in homocysteine-induced oxidative stress and apoptosis in human umbilical vein endothelial cells. Cardiovasc Toxicol, 5: 9–20, 2005.
88.
DrenckhahnD and FrankeRP. Ultrastructural organization of contractile and cytoskeletal proteins in glomerular podocytes of chicken, rat, and man. Lab Invest, 59: 673–682, 1988.
89.
EddyAA. Molecular insights into renal interstitial fibrosis. J Am Soc Nephrol, 7: 2495–2508, 1996.
90.
El-BachaRS and MinnA. Drug metabolizing enzymes in cerebrovascular endothelial cells afford a metabolic protection to the brain. Cell Mol Biol, 45: 15–23, 1999.
91.
EngelhardtB, CarareRO, BechmannI, FlügelA, LamanJD, and WellerRO. Vascular, glial, and lymphatic immune gateways of the central nervous system. Acta Neuropathol, 132: 317–338, 2016.
92.
EngelhardtB, VajkoczyP, and WellerRO. The movers and shapers in immune privilege of the CNS. Nat Immunol, 18: 123–131, 2017.
93.
EvansTW. Review article: albumin as a drug—biological effects of albumin unrelated to oncotic pressure. Aliment Pharmacol Ther, 16: 6–11, 2002.
94.
FanaliG, di MasiA, TrezzaV, MarinoM, FasanoM, and AscenziP. Human serum albumin: from bench to bedside. Mol Aspects Med, 33: 209–290, 2012.
95.
FarrallAJ and WardlawJM. Blood-brain barrier: ageing and microvascular disease—systematic review and meta-analysis. Neurobiol Aging, 30: 337–352, 2009.
96.
FasanoM, CurryS, TerrenoE, GallianoM, FanaliG, NarcisoP, NotariS, and AscenziP. The extraordinary ligand binding properties of human serum albumin. IUBMB Life, 57: 787–796, 2005.
97.
FernandesPA and RamosMJ. Theoretical insights into the mechanism for thiol/disulfide exchange. Chem Eur J, 10: 257–266, 2004.
98.
FindlayVJ, TownsendDM, MorrisTE, FraserJP, HeL, and TewKD. A novel role for human sulfiredoxin in the reversal of glutathionylation. Cancer Res, 66: 6800–6806, 2006.
99.
FinkelsteinJD, KyleWE, MartinJL, and PickAM. Activation of cystathionine synthase by adenosylmethionine and adenosylethionine. Biochem Biophys Res Commun, 66: 81–87, 1975.
100.
FinkelsteinJD, MartinJJ, and HarrisBJ. Methionine metabolism in mammals. The methionine-sparing effect of cystine. J Biol Chem, 263: 11750-11754, 1988.
101.
FinnTE, NunezAC, SundeM, and Easterbrook-SmithSB. Serum albumin prevents protein aggregation and amyloid formation and retains chaperone-like activity in the presence of physiological ligands. J Biol Chem, 287: 21530–21540, 2012.
102.
FontecaveM, AttaM, and MulliezE. S-adenosylmethionine: nothing goes to waste. Trends Biochem Sci, 29: 243–249, 2004.
103.
FosterDC, YoshitakeS, and DavieEW. The nucleotide sequence of the gene for human protein C (DNA sequence analysis/vitamin K-dependent proteins/blood coagulation). Proc Natl Acad Sci U S A 82, 467, 3–4677, 1985.
104.
FratelliM, DemolH, PuypeM, CasagrandeS, EberiniI, SalmonaM, BonettoV, MengozziM, DuffieuxF, BachiA, VandekerckhoveJ, GianazzaE, and GhezziP. Identification by redox proteomics of glutathionylated proteins in oxidatively stressed human T lymphocytes. Proc Natl Acad Sci U S A, 99: 3505–3510, 2002.
105.
FreyE. Albumin binding ligands and albumin conjugate uptake by cancer cells. Diabetol Metab Syndr, 3: 11, 2011.
106.
FrosaliS, LeoniniA, EttorreA, Di MaioG, NutiS, TavariniS, Di SimplicioP, and Di StefanoA. Role of intracellular calcium and S-glutathionylation in cell death induced by a mixture of isothiazolinones in HL60 cells. Biochim Biophys Acta, 1793: 572–583, 2009.
107.
FujiwaraS and AmisakiT. Steric and allosteric effects of fatty acids on the binding of warfarin to human serum albumin revealed by molecular dynamics and free energy calculations. Chem Pharm Bull (Tokyo), 59: 860–867, 2011.
108.
FujiwaraS and AmisakiT. Fatty acid binding to serum albumin: molecular simulation approaches. Biochim Biophys Acta, 1830: 5427–5434, 2013.
109.
FujiwaraS-I and AmisakiT. Molecular dynamics study of conformational changes in human serum albumin by binding of fatty acids. Proteins, 64: 730–739, 2006.
110.
GalloglyMM and MieyalJJ. Mechanisms of reversible protein glutathionylation in redox signaling and oxidative stress. Curr Opin Pharmacol, 7: 381–391, 2007.
111.
GanapathyPS, WhiteRE, HaY, BozardBR, McNeilPL, CaldwellRW, KumarS, BlackSM, and SmithSB. The role of N-methyl-D-aspartate receptor activation in homocysteine-induced death of retinal ganglion cells. Invest Ophthalmol Vis Sci, 52: 5515–5524, 2011.
112.
GekleM. Renal tubule albumin transport. Annu Rev Physiol, 67: 573–594, 2005.
113.
GerberDA, CohenN, and GiustraR. The ability of nonsteroid anti-inflammatory compounds to accelerate a disulfide interchange reaction of serum sulfhydryl groups and 5,5′-dithiobis(2-nitrobenzoic acid). Biochem Pharmacol, 16: 115–123, 1967.
114.
GhezziP and Di SimplicioP. Glutathionylation pathways in drug response. Curr Opin Pharmacol, 7: 398–403, 2007.
115.
GlowackiM and JakubowskiH. Cross-talk between Cys34 and lysine residues in human serum albumin revealed by N-homocysteinylation. J Biol Chem, 279: 10864–10871, 2004.
116.
GoY-M and JonesDP. Cysteine/cystine redox signaling in cardiovascular disease. Free Radic Biol Med, 50: 495–509, 2011.
117.
GonçalvesGL, Costa-PessoaJM, ThiemeK, LinsBB, and Oliveira-SouzaM. Intracellular albumin overload elicits endoplasmic reticulum stress and PKC-delta/p38 MAPK pathway activation to induce podocyte apoptosis. Sci Rep, 8: 18012, 2018.
118.
GorrizJL and Martinez-CastelaoA. Proteinuria: detection and role in native renal disease progression. Transplant Rev (Orlando), 26: 3–13, 2012.
119.
GrahammerF, SchellC, and HuberTB. The podocyte slit diaphragm—from a thin grey line to a complex signalling hub. Nat Rev Nephrol, 9: 587–598, 2013.
120.
GruenbergJ, GriffithsG, and HowellKE. Characterization of the early endosome and putative endocytic carrier vesicles in vivo and with an assay of vesicle fusion in vitro. J Cell Biol, 108: 1301–1316, 1989.
121.
GryzunovYA, ArroyoA, VigneJL, ZhaoQ, TyurinVA, HubelCA, GandleyRE, VladimirovYA, TaylorRN, and KaganVE. Binding of fatty acids facilitates oxidation of cysteine-34 and converts copper-albumin complexes from antioxidants to prooxidants. Arch Biochem Biophys, 413: 53–66, 2003.
122.
GundryRL, FuQ, JelinekCA, Van EykJE, and CotterRJ. Investigation on an albumin-enriched fraction of human serum and its albuminome. Proteomics Clin Appl, 1: 73–88, 2007.
123.
GuptaD and LisCG. Pretreatment serum albumin as a predictor of cancer survival: a systematic review of the epidemiological literature. Nutr J, 9: 69–85, 2010.
124.
GuptaV and CarrollKS. Sulfenic acid chemistry detection and cellular lifetime. Biochim Biophys Acta, 1840: 847–875, 2014.
125.
HackettSF and CampochiaroPA. Implication of protein carboxymethylation in retinal pigment epithelial cell chemotaxis. Ophthalmic Res, 20: 54–59, 1988.
126.
HajjarKA. Homocysteine-induced modulation of tissue plasminogen activator binding to its endothelial cell membrane receptor. J Clin Invest, 91: 2873–2879, 1993.
127.
HajjarKA, MauriL, JacovinaAT, ZhongF, MirzaUA, PadovanJC, and ChaitBT. Tissue plasminogen activator binding to the annexinII tail domain. Direct modulation by homocysteine. J Biol Chem, 273: 9987–9993, 1998.
128.
HalliwellB. Albumin—an important extracellular antioxidant?. Biochem Pharmacol, 37: 569–571, 1988.
129.
HandyDE, CastroR, and LoscalzoJ. Epigenetic modifications: basic mechanisms and role in cardiovascular disease. Circulation, 123: 2145–2156, 2011.
130.
HandyDE, ZhangY, and LoscalzoJ. Homocysteine down-regulates cellular glutathione peroxidase (GPx1) by decreasing translation. J Biol Chem, 280: 15518–15525, 2005.
131.
HansenJM, GoYM, and JonesDP. Nuclear and mitochondrial compartmentation of oxidative stress and redox signaling. Annu Rev Pharmacol Toxicol, 46: 215–234, 2006.
HaraldssonB and NyströmJ. The glomerular endothelium: new insights on function and structure. Curr Opin Nephrol Hypertens, 21: 258–263, 2012.
134.
HaraldssonBR, NystroJ, and DeenWD. Properties of the glomerular barrier and mechanisms of proteinuria. Physiol Rev, 88: 451–487, 2008.
135.
HawkinsBT and DavisTP. The blood-brain barrier/neurovascular unit in health and disease. Pharmacol Rev, 57: 173–185, 2005.
136.
HaymannJP, LevraudJP, BouetS, KappesV, HagegeJ, NguyenG, XuY, RondeauE, and SraerJD. Characterization and localization of the neonatal Fc receptor in adult human kidney. J Am Soc Nephrol, 11: 632–639, 2000.
137.
HeXM and CarterDC. Atomic structure and chemistry of human serum albumin. Nature, 358: 209–215, 1992.
138.
HerrmannW, HerrmannM, and ObeidR. Hyperhomocysteinaemia: a critical review of old and new aspects. Curr Drug Metab, 8: 17–31, 2007.
139.
HilhorstE, IskanderAS, ChenTBRA, and PanditUK. Alkyl transfer from quaternary ammonium salts to cobalt (I): model for the cobalamin-dependent methionine synthase reaction. Tetrahedron, 50: 8863–8870, 1994.
140.
HoefmanS, OttevaereI, BaumeisterJ, and Sargentini-MaierML. Pre-clinical intravenous serum pharmacokinetics of albumin binding and non-half-life extended Nanobodies. Antibodies, 4: 141–156, 2015.
141.
HolewinskiRJ, JinZ, PowellMJ, MaustMD, and Van EykJE. A fast and reproducible method for albumin isolation and depletion from serum and cerebrospinal fluid. Proteomics, 13: 743–750, 2013.
142.
Homocysteine StudiesCollaboration. Homocysteine and risk of ischemic heart disease and stroke A meta-analysis. JAMA, 288: 2015–2022, 2002.
143.
HradecJ. Metabolism of serum albumin in tumour-bearing rats. Br J Cancer, 12: 290–304, 1958.
144.
HultbergB, AnderssonA, and IsakssonA. Hypomethylation as a cause of homocysteine-induced cell damage in human cell lines. Toxicology, 147: 69–75, 2000.
145.
IadecolaC. Neurovascular regulation in the normal brain and in Alzheimer's disease. Nat Rev Neurosci, 5: 347–360, 2004.
146.
IgnestiG, BanchelliMG, PirisinoR, RaimondiL, and BuffoniF. Catalytic properties of serum albumin. Pharmacol Res Commun, 15: 569–579, 1983.
147.
IlzeckaJ. The structure and function of blood-brain barrier in ischaemic brain stroke process. Ann Univ Mariae Curie Sklodowska Med, 51: 123–127, 1996.
148.
InnisSM, DavidsonAG, ChenA, DyerR, MelnykS, and JamesSJ. Increased plasma homocysteine and S-adenosylhomocysteine and decreased methionine is associated with altered phosphatidylcholine and phosphatidylethanolamine in cystic fibrosis. J Pediatr, 143: 351–356, 2003.
149.
IoannidouS, DeinhardtK, MiotlaJ, BradleyJ, CheungE, SamuelssonS, NgYS, and ShimaDT. An in vitro assay reveals a role for the diaphragm protein PV-1 in endothelial fenestra morphogenesis. Proc Natl Acad Sci U S A, 103: 16770–16775, 2006.
150.
IshimaY, SawaT, Kragh-HansenU, MiyamotoY, MatsushitaS, AkaikeT, and OtagiriM. S-nitrosylation of human variant albumin liprizzi (R410C) confers potent antibacterial and cytoprotective properties. J Pharmacol Exp Ther, 320: 969–977, 2007.
151.
IsholaDA, PostJA, van TimmerenMM, BakkerSJL, GoldschmedingR, KoomansHA, BraamB, and JolesJA. Albumin-bound fatty acids induce mitochondrial oxidant stress and impair antioxidant responses in proximal tubular cells. Kidney Int, 70: 724–731, 2006.
152.
JacobsenDW, GatautisVJ, GreenR, RobinsonK, SavonSR, SecicM, JiJ, OttoJM, and TaylorLMJr. Rapid HPLC determination of total homocysteine and other thiols in serum and plasma: sex differences and correlation with cobalamin and folate concentrations in healthy subjects. Clin Chem, 40: 873–881, 1994.
153.
JakubowskiH. Homocysteine modification in protein structure/function and human disease. Physiol Rev, 99: 555–604, 2019.
154.
JamaluddinS, ChenI, YangF, JiangX, JanM, LiuX, SchaferAI, DuranteW, YangX, and WangH. Homocysteine inhibits endothelial cell growth via DNA hypomethylation of the cyclin A gene. Blood, 110: 3648–3655, 2007.
155.
JencksDA and MathewsRG. Allosteric inhibition of methylenetetrahydrofolate reductase by adenosylmethionine. Effects of adenosylmethionine and NADPH on the equilibrium between active and inactive forms of the enzyme and on the kinetics of approach to equilibrium. J Biol Chem, 262: 2485–2493, 1987.
156.
JonesDP. Radical-free biology of oxidative stress. Am J Physiol Cell Physiol, 295: C849–C868, 2008.
157.
JonesDP and SiesE. The redox code. Antioxid Redox Signal, 23: 734–746, 2015.
158.
JunghansRP and AndersonCL. The protection receptor forIgG catabolism is the,32-microglobulin-containing neonatal intestinal transport receptor. Proc Natl Acad Sci U S A, 93: 5512–5516, 1996.
159.
KandasamyY, SmithR, LumbersER, and RuddD. Nephrin—a biomarker of early glomerular injury. Biomark Res, 2: 21, 2014.
160.
KangSS, WongPW, and MalinowMR. Hyperhomocyst(e)inemia as a risk factor for occlusive vascular disease. Annu Rev Nutr, 12: 279–298, 1992.
161.
KaufmanRJ. Orchestrating the unfolded protein response in health and disease. J Clin Invest, 110: 1389–1398, 2002.
162.
KawachiH and FukusumiY. New insight into podocyte slit diaphragm, a therapeutic target of proteinuria. Clin Exp Nephrol, 24: 193–204, 2020.
163.
Kees-FoltsK, SadowJ, and SchreinerGF. Tubular catabolism of albumin is associated with the release of an inflammatory lipid. Kidney Int, 45: 1697–1709, 1994.
164.
KimH, FarissRN, ZhangC, RobinsonSB, ThillM, and CsakyKG. Mapping of the neonatal Fc receptor in the rodent eye. Invest Ophthalmol Vis Sci, 49: 2025–2029, 2008.
165.
KimJ, BronsonCL, HaytonWL, RadmacherMD, RoopenianDC, RobinsonJM, and AndersonCL. Albumin turnover: FcRn-mediated recycling saves as much albumin from degradation as the liver produces. Am J Physiol Gastrointest Liver Physiol, 290: G352–G360, 2006.
166.
KimJ, HaytonWL, RobinsonJM, and AndersonCL. Kinetics of FcRn-mediated recycling of IgG and albumin in human: pathophysiology and therapeutic implications using a simplified mechanism-based model. Clin Immunol, 122: 146–155, 2007.
167.
KimJK, MastronardiFG, WoodDD, LubmanDM, ZandR, and MoscarelloMA. Multiple sclerosis: an important role for post-translational modifications of myelin basic protein in pathogenesis. Mol Cell Proteomics, 2: 453–462, 2003.
168.
KimballSR, HoretskyRL, and JeffersonLS. Hormonal regulation of albumin gene expression in primary cultures of rat hepatocytes. Am J Physiol, 268: E6–E14, 1995.
169.
Knudsen SandM, BernJ, NielsenJ, NoordzijHT, SandlieI, and AndersenJT. Unraveling the interaction between FcRn and albumin: opportunities for design of albumin-based therapeutics. Front Immunol, 5: 682–703, 2015.
170.
KobayashiN, SuzukiY, TsugeT, OkumuraK, RaC, andTominoY. FcRn-mediated transcytosis of immunoglobulinG in human renal proximal tubular epithelial. cells. Am J Physiol Renal Physiol, 282: F358–F365, 2002.
171.
KogaM and KasayamaS. Clinical impact of glycated albumin as another glycemic control marker. Endocr J, 57: 751–762, 2010.
172.
KosowerNS, KosowerNS, and KoppelRL. Sensitivity of hemoglobin thiol groups within red blood cells of rat during oxidation of glutathione. Eur J Biochem, 77: 529–534, 1977.
173.
KoutsiA, PapapanagiotouA, and PapavassiliouAG. Thrombomodulin: from haemostasis to inflammation and tumourigenesis. Int J Biochem Cell Biol, 40: 1669–1673, 2008.
174.
Kragh-HansenU. Molecular and practical aspects of the enzymatic properties of human serum albumin and of albumin-ligand complexes. Biochim Biophys Acta, 1830: 5535–5544, 2013.
175.
KratzF. DOXO-EMCH (INNO-206): the first albumin-binding prodrug of doxorubicin to enter clinical trials. Expert Opin Investig Drugs, 16: 855–866, 2007.
176.
KratzF. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J Control Release, 132: 171–183, 2008.
177.
KuoTT, BakerK, YoshidaM, QiaoS-W, AvesonVG, LencerWI, and BlumbergRS. Neonatal Fc receptor: from immunity to therapeutics. J Clin Immunol, 30: 777–789, 2010.
178.
LarochelleC, AlvarezJI, and PratA. How do immune cells overcome the blood-brain barrier in multiple sclerosis?. FEBS Lett, 585: 3770–3780, 2011.
LeclercD, WilsonA, DumasR, GafuikC, SongD, WatkinsD, HengHH, RommensJM, SchererSW, RosenblattDS, and GravelRA. Cloning and mapping of a cDNA for methionine synthase reductase, a flavoprotein defective in patients with homocystinuria. Proc Natl Acad Sci U S A, 95: 3059–3064, 1998.
181.
LemusHN, WarringtonAE, and RodriguezM. Multiple sclerosis: mechanisms of disease and strategies for myelin and axonal repair. Neurol Clin, 36: 1–11, 2018.
182.
LentzSR and SadlerJE. Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine. J Clin Invest, 88: 1906–1914, 1991.
183.
LentzSR and SadlerJE. Homocysteine inhibits von Willebrand factor processing and secretion by preventing transport from the endoplasmic reticulum. Blood, 81: 683–689, 1993.
184.
LeVineSM. Albumin and multiple sclerosis. BMC Neurol, 16: 47, 2016.
LiptonSA, KimV-K, ChoiV-B, KumarS, D'EmiliaDM, RayuduPV, ArnelleDR, and StamlerJS. Neurotoxicity associated with dual actions of homocysteine at the N-methyl-D-aspartate receptor. Proc Natl Acad Sci U S A, 94: 5923–5928, 1997.
187.
LoscalzoJ. Homocysteine trials—clear outcomes for complex reasons. N Engl J Med, 354: 1629–1632, 2006.
188.
LuSC, Martínez-ChantarML, and MatoJM. Methionine adenosyltransferase and S-adenosylmethionine in alcoholic liver disease. J Gastroenterol Hepatol, 21: S61–S64, 2006.
189.
LuSC and MatoJM. S-adenosylmethionine in liver health, injury, and cancer. Physiol Rev, 92: 1515–1542, 2012.
190.
LucchinettiCF, BrueckW, RodriguezM, and LassmannH. Multiple sclerosis: lessons learned from neuropathology. Semin Neurol, 18: 337–349, 1998.
191.
LukaZ, MuddSH, and WagnerC. Glycine N-methyltransferase and regulation of S-adenosylmethionine levels. J Biol Chem, 284: 22507–22511, 2009.
192.
MalinowMR. Hyperhomocyst(e)inemia: a common and easily reversible risk factor for occlusive disease. Circulation, 81: 2004–2006, 1990.
193.
MargarsonM and SoniN. Serum albumin: touchstone or totem?. Anaesthesia, 53: 789–803, 1998.
194.
MarkhamGD and PajaresMA. Structure-function relationships in methionine adenosyltransferases. Cell Mol Life Sci, 66: 636–648, 2009.
195.
MaronBA and LoscalzoJ. The treatment of hyperhomocysteinemia. Annu Rev Med, 60: 39–54, 2009.
196.
Marti-CarvajalA J, SolaI, LathyrisD, and DayerM. Homocysteine-lowering interventions for preventing cardiovascular events (review). Cochrane Database Syst Rev, 8: CD006612, 2017.
197.
MartinsJP, KennedyPJ, SantosHA, BarriasC, and SarmentoB. A comprehensive review of the neonatal Fc receptor and its application in drug delivery. Pharmacol Ther, 161: 22–39, 2016.
198.
MatthewsRG. Methylenetetrahydrofolate reductase: a common human polymorphism and its biochemical implications. Chem Rec, 2: 4–12, 2002.
McCarthyKM, YoongY, and SimisterNE. Bidirectional transcytosis of IgG by the rat neonatal Fc receptor expressed in a rat kidney cell line: a system to study protein transport across epithelia. J Cell Sci, 113: 1277–1285, 2000.
201.
McCullyKS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol, 56: 111–128, 1969.
202.
MercieP, GarnierO, LascosteL, RenardM, ClosseC, DurrieuF, MaritG, BoisseauRM, and BellocF. Homocysteine-thiolactone induces caspase-independent vascular endothelial cell death with apoptotic features. Apoptosis, 5: 403–411, 2000.
203.
MerlotAM, KalinowskiDS, and RichardsonDR. Unraveling the mysteries of serum albumin-more than just a serum protein. Front Physiol, 5: 299, 2014.
MiuraK, IshiiT, SugitaY, and BannaiS. Cystine uptake and glutathione level in endothelial cells exposed to oxidative stress. Am J Physiol, 262: C50–C58, 1992.
206.
MontagneA, BarnesSR, SweeneyMD, HallidayMR, SagareAP, ZhaoZ, TogaAW, JacobsRE, LiuCY, AmezcuaL, HarringtonMG, ChuiHC, LawM, and ZlokovicBV. Blood-brain barrier breakdown in the aging human hippocampus. Neuron, 85: 296–302, 2015.
207.
Morganti-KossmannMC, RancanM, StahelPF, and KossmannT. Inflammatory response in acute traumatic brain injury: a double-edged sword. Curr Opin Crit Care, 8: 101–105, 2002.
208.
MoriyamaT, SasakiK, KarasawaK, UchidaK, and NittaK. Intracellular transcytosis of albumin in glomerular endothelial cells after endocytosis through caveolae. J Cell Physiol, 232: 3565–3573, 2017.
209.
MorrisG and BerkM. The many roads to mitochondrial dysfunction in neuroimmune and neuropsychiatric disorders. BMC Med, 13: 68, 2015.
210.
NagyP. Kinetics and mechanisms of thiol–disulfide exchange overing direct substitution and thiol oxidation-mediated pathways. Antioxid Redox Signal, 18: 1623–1641, 2013.
211.
NettoLE, de OliveiraMA, TairumCA, and da Silva NetoJF. Conferring specificity in redox pathways by enzymatic thiol/disulfide exchange reactions. Free Radic Res, 50: 206–245, 2016.
212.
NeumannCA, CaoJ, and ManevichY. Peroxiredoxin 1 and its role in cell signaling. Cell Cycle, 8: 4072–4078, 2009.
213.
NeumannE, FreiE, FunkD, BeckerMD, SchrenkHH, Müller-LadnerU, and FiehnC. Native albumin for targeted drug delivery. Expert Opin Drug Deliv, 7: 915–925, 2010.
214.
NicholsonJP, WolmaransMR, and ParkGR. The role of albumin in critical illness. Br J Anaesth, 85: 599–610, 2000.
215.
NielsenR, ChristensenEI, and BirnH. Megalin and cubilin in proximal tubule protein reabsorption: from experimental models to human disease. Kidney Int, 89: 58–67, 2016.
216.
NonakaH, TsujinoT, WatariY, EmotoN, and YokoyamaM. Taurine prevents the decrease in expression and secretion of extracellular superoxide dismutase induced by homocysteine: amelioration of homocysteine-induced endoplasmic reticulum stress by taurine. Circulation, 104: 1165–1170, 2001.
217.
NoseworthyJH. Progress in determining the causes and treatment of multiple sclerosis. Nature, 399: A40–A47, 1999.
218.
NygårdO, NordrehaugJE, RefsumH, UelandPM, FarstadM, and VollsetSE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med, 337: 230–236, 1997.
219.
ObeidR and HerrmannW. Mechanisms of homocysteine neurotoxicity in neurodegenerative diseases with special reference to dementia. FEBS Lett 580, 299, 4–3005, 2006.
220.
ObermeierB, DanemanR, and RansohoffRM. Development, maintenance and disruption of the blood-brain barrier. Nat Med, 19: 1584–1594, 2013.
221.
OgawaT, KimotoM, and SasaokaK. Purification and properties of a new enzymeNG, NG-dimethylarginine dimethylaminohydrolase, from rat kidney. J Biol Chem, 264: 10205–10209, 1989.
222.
OkamotoCT. Endocytosis and transcytosis. Adv Drug Deliv Rev, 29: 215–228, 1998.
223.
OkamotoT, TanigamiH, SuzukiK, and ShimaokaM. Thrombomodulin: a bifunctional modulator of inflammation and coagulation in sepsis. Crit Care Res Pract, 2012: 614545, 2012.
224.
OlmezI and OzyurtH. Reactive oxygen species and ischemic cerebrovascular disease. Neurochem Int, 60: 208–212, 2012.
225.
OlteanuH and BanerjeeR. Human methionine synthase reductase, a soluble P-450 reductase-like dual flavoprotein, is sufficient for NADPH-dependent methionine synthase. activation. J Biol Chem, 38: 35558–35563, 2001.
226.
OlteanuH, WolthersKR, MunroAW, ScruttonNS, and Banerjee R. Kinetic and thermodynamic characterization of the common polymorphic variants of human methionine synthase reductase, Biochemistry, 43: 1988–1997, 2004.
227.
OokhtensM and KaplowitzN. Role of the liver in interorgan homeostasis of glutathione and cyst(e)ine. Semin Liver Dis, 18: 313–329, 1988.
228.
PajaresMA, DuránC, CorralesF, PliegoMM, and MatoJM. Modulation of rat liver S-adenosylmethionine synthetase activity by glutathione. J Biol Chem, 267: 17598–17605, 1992.
229.
PardridgeWM, EisenbergJ, and CefaluWT. Absence of albumin receptor on brain capillaries in vivo or in vitro. Am J Physiol, 249: E264–E267, 1985.
230.
ParkJB. Reduction of dehydroascorbic acid by homocysteine. Biochim Biophys Acta, 1525: 173–179, 2001.
231.
ParkJW, MieyalJJ, RheeSG, and ChockPB. Deglutathionylation of 2-Cys peroxiredoxin is specifically catalyzed by sulfiredoxin. J Biol Chem, 284: 23364–23374, 2009.
232.
ParksJS, CistolaDP, SmallDM, and HamiltonJA. Interactions of the carboxyl group of oleic acid with bovine serum albumin: a 13C NMR. study. J Biol Chem, 258: 9262–9269, 1983.
233.
ParvingHP and GyntelbergF. Transcapillary escape rate of albumin and plasma volume in essential hypertension. Circ Res, 32: 643–651, 1973.
234.
PatcheJ, GirardD, CatanA, BoyerF, DobiA, PlanesseC, DiotelN, Guerin-DubourgA, BaterP, BravoSB, Paradela-DobarroB, AlvarezE, EssopMF, MeilhacO, BourdonE, and RondeauP. Diabetes-induced hepatic oxidative stress: a new pathogenic role for glycated albumin. Free Radic Biol Med, 102: 133–148, 2017.
235.
Perła-KajánJ, TwardowskiT, and JakubowskiH. Mechanisms of homocysteine toxicity in humans. Amino Acids, 32: 561–572, 2007.
236.
PernaAF, lngrossoD, ZappiaV, GallettiP, CapassoG, and De SantoNG. Enzymatic methyl esterification of erythrocyte membrane proteins is impaired in chronic renal failure: evidence for high levels of the natural inhibitor S-adenosylhomocysteine. J Clin Invest, 91: 2497–2503, 1993.
237.
PetersT. All About Albumin. Biochemistry, Genetics and Medical Applications. San Diego, CA: Academic Press, 1996.
238.
PetitpasI, GruneT, BhattacharyaAA, and CurryS. Crystal structures of human serum albumin complexed with monounsaturated and polyunsaturated fatty acids. J Mol Biol, 314: 955–960, 2001.
239.
PetrasM, TatarkovaZ, KovalskaM, MokraD, DobrotaD, LehotskyJ, and DrgovaA. Hyperhomocysteinemia as a risk factor for the neuronal system disorders. J Physiol Pharmacol, 65: 15–23, 2014.
240.
PirisinoR, Di SimplicioP, IgnestiG, BianchiG, and BarberaP. Sulfhydryl groups and peroxidase-like activity of albumin as scavenger of organic peroxides. Pharmacol Res Commun, 20: 545–552, 1988.
241.
PoddarR and PaulS. Homocysteine-NMDA receptor mediated activation of extracellular-signal regulated kinase leads to neuronal cell death. J Neurochem, 110: 1095–1106, 2009.
242.
PoddarR, SivasubramanianN, DiBelloPM, RobinsonK, and JacobsenDW. Homocysteine induces expression and secretion of monocyte chemoattractant protein-1 and interleukin-8 in human aortic endothelial cells: implications for vascular disease. Circulation, 103: 2717–2723, 2001.
243.
PrestonJE, AbbottNJ, and BegleyDJ. Transcytosis of macromolecules at the blood-brain barrier. Adv Pharmacol, 71: 147–163, 2014.
244.
PrioraR, CoppoL, MargaritisA, Di GiuseppeD, FrosaliS, SummaD, HeoJ, and Di SimplicioP. The control of S-thiolation by cysteine via gamma-glutamyltranspeptidase and thiol exchanges in erythrocytes and plasma of diamide-treated rats. Toxicol Appl Pharmacol, 242: 333–343, 2010.
245.
PyzikM, RathT, KuoTT, WinS, BakerK, HubbardJJ, GrenhaR, GandhiA, KrämerTD, MezoAR, TaylorZS, McDonnellK, NienaberV, AndersenJT, MizoguchiA, BlumbergL, PurohitS, JonesSD, ChristiansonG, LencerWI, SandlieI, KaplowitzN, RoopenianDC, and BlumbergRS. Hepatic FcRn regulates albumin homeostasis and susceptibility to liver injury. Proc Natl Acad Sci U S A, 114: E2862–E2871, 2017.
246.
RafikovaO, RafikovR, and NudlerE. Catalysis of S-nitrosothiols formation by serum albumin: the mechanism and implication in vascular control. Proc Natl Acad Sci U S A, 99: 5913–5918, 2002.
247.
RaftosJE, WhillierS, ChapmanBE, and KuchelPW. Kinetics of uptake and deacetylation of N-acetylcysteine by human erythrocytes. Int J Biochem Cell Biol, 39: 1698–1706, 2007.
248.
RamsaransingGSM, FokkemaMR, TeelkenA, ArutjunyanAV, KochM, and De KeyserJ. Plasma homocysteine levels in multiple sclerosis. J Neurol Neurosurg Psychiatry, 77: 189–192, 2006.
249.
RathT, BakerK, PyzikM, and BlumbergRS. Regulation of immune responses by the neonatal Fc receptor and its therapeutic implications. Front Immunol, 5: 664, 2015.
250.
RimacH, Debeljak Ž, BojićM, and MillerL. Displacement of drugs from human serum albumin: from molecular interactions to clinical significance. Curr Med Chem, 24: 1930–1947, 2017.
251.
RondeauP and BourdonE. The glycation of albumin: structural and functional impacts. Biochimie, 93: 645–658, 2011.
252.
RoohkHV, ZaidiAR, and PatelD. Glycated albumin (GA) and inflammation: role ofGA as a potential marker of. inflammation. Inflamm Res, 67: 21–30, 2018.
253.
RookyardAV, PaulechJ, ThyssenS, LiddyKA, PuckeridgeM, LiDK, WhiteMY, and CordwellSG. A global profile of reversible and irreversible cysteine redox post-translational modifications during myocardial ischemia/reperfusion injury and antioxidant intervention. Antioxid Redox Signal, 34: 11–31, 2021.
254.
RossiR, BarraD, BellelliA, BoumisG, CanofeniS, Di SimplicioP, LusiniL, PascarellaS, and AmiconiG. Fast-reacting thiols in rat hemoglobins can intercept damaging species in erythrocytes more efficiently than glutathione. J Biol Chem, 273: 19198–19206, 1998.
255.
RothschildMA, OratzM, and SchreiberSS. Albumin metabolism. Gastroenterology, 64: 324–337, 1973.
256.
RuggenentiP and RemuzziG. The role of protein traffic in the progression of renal diseases. Annu Rev Med, 51: 315–327, 2000.
257.
RuotsalainenV, LjungbergP, WartiovaaraJ, LenkkeriU, KestiläM, JalankoH, HolmbergC, and TryggvasonK. Nephrin is specifically located at the slit diaphragm of glomerular podocytes. Proc Natl Acad Sci U S A, 96: 7962–7967, 1999.
258.
SahaS, ChakrabortyPK, XiongX, DwivediSKD, MustafiSB, LeighNR, RamchandranR, MukherjeeP, and BhattacharyaR. Cystathionine β-synthase regulates endothelial function via protein S-sulfhydration. FASEB J, 30: 441–456, 2016.
259.
SandovalRM, WagnerMC, PatelM, Campos-BilderbackSB, RhodesGJ, WangE, WeanSE, ClendenonSS, and MolitorisBA. Multiple factors influence glomerular albumin permeability in rats. J Am Soc Nephrol, 23: 447–457, 2012.
260.
SaravM, WangY, HackBK, ChangA, JensenM, BaoL, and QuiggRJ. Renal FcRn reclaims albumin but facilitates elimination of IgG. J Am Soc Nephrol, 20: 1941–1952, 2009.
261.
SatchellSC and BraetF. Glomerular endothelial cell fenestrations: an integral component of the glomerular filtration barrier. Am J Physiol Renal Physiol, 296: F947–F956, 2009.
262.
SaundersNR, EkCJ, HabgoodMD, and DziegielewskaKM. Barriers in the brain: a renaissance?. Trends Neurosci, 31: 279–286, 2008.
263.
SbarouniE, GeorgiadouP, and VoudrisV. Ischemia modified albumin changes—review and clinical implications. Clin Chem Lab Med, 49: 177–184, 2011.
264.
SchrauzerGN and DeutschE. Reactions of cobalt(I) supernucleophiles. The alkylation of vitamin B12s cobaloximes(I), and related compounds. J Am Chem Soc, 91: 3341–3350, 1969.
265.
SchrauzerGN and WindgassenRJ. On cobaloximes with cobalt-sulfur bonds and some model studies related to cobamide-dependent methyl-group-transfer. J Am Chem Soc, 89: 3607–3612, 1967.
266.
SchubertW, FrankPG, RazaniB, ParkDS, ChowCW, and LisantiMP. Caveolae-deficient endothelial cells show defects in the uptake and transport of albumin in vivo. J Biol Chem, 276: 48619–48622, 2001.
267.
ScottJM and WeirDG. The methyl folate trap. A physiological response in man to prevent methyl group deficiency in kwashiorkor (methionine deficiency) and an explanation for folic-acid induced exacerbation of subacute combined degeneration in pernicious anaemia. Lancet, 15: 337–340, 1981.
268.
SibaniS, MelnykS, PogribnyIP, WangW, Hiou-TimF, DengL, TraslerJ, JamesSJ, and RozenR. Studies of methionine cycle intermediates (SAMSAH), DNA methylation and the impact of folate deficiency on tumor numbers inMin. mice. Carcinogenesis, 23: 61–65, 2002.
269.
SiennickaA, ZuchowskiM, CheltowskiK, CnotliwyM, ClarkJS, and JastrzebskaM. Homocysteine-enhanced proteolytic and fibrinolytic processes in thin intraluminal thrombus and adjacent wall of abdominal aortic aneurysm: study in vitro. Biomed Res Int, 3205324: 2018, 2018.
270.
SmithAD and RefsumH. HomocysteineB vitamins, and cognitive Impairment. Annu Rev Nutr, 36: 221–239, 2016.
SpectorAA. Structure and lipid binding properties of serum albumin. Methods Enzymol, 128: 320–339, 1986.
273.
StanyonHF and VilesJH. Human serum albumin can regulate amyloid-β peptide fiber growth in the brain interstitium: implications forAlzheimer. disease. J Biol Chem, 287: 28163–28168, 2012.
274.
StehleG, SinnH, WunderA, SchrenkHH, StewartJC, HartungG, Maier-BorstW, and HeeneDL. Plasma protein (albumin) catabolism by the tumor itself–implications for tumor metabolism and the genesis of cachexia. Crit Rev Oncol Hematol, 26: 77–100, 1997.
SteinmanL. A molecular trio in relapse and remission in multiple sclerosis. Nat Rev Immunol, 9: 440–447, 2009.
277.
StephanJP, MaoW, FilvaroffE, CaiL, RabkinR, and PanG. Albumin stimulates the accumulation of extracellular matrix in renal tubular epithelial cells. Am J Nephrol, 24: 14–19, 2004.
278.
StoopsEH and CaplanMJ. Trafficking to the apical and basolateral membranes in polarized epithelial cells. J Am Soc Nephrol, 25: 1375–1386, 2014.
279.
StruckAW, ThompsonML, WongLS, and MicklefieldJ. S-adenosyl-methionine-dependent methyltransferases: highly versatile enzymes in biocatalysis, biosynthesis and other biotechnological applications. Chembiochem, 13: 2642–2655, 2012.
280.
StuhlingerMC, TsaoPS, HerJH, KimotoM, BalintRF, and CookeJP. Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine. Circulation, 104: 2569–2575, 2001.
281.
SudlowG, BirkettDJ, and WadeDN. The characterization of two specific drug binding sites on human serum albumin. Mol Pharmacol, 11: 824–832, 1975.
282.
SudlowG, BirkettDJ, and WadeDN. Further characterization of specific drug binding sites on human serum albumin. Mol Pharmacol, 12: 1052–1061, 1976.
283.
SugioS, KashimaA, MochizukiS, NodaM, and KobayashiK. Crystal structure of human serum albumin at 2.5 A resolution. Protein Eng, 12: 439–446, 1999.
284.
SuhJH and MinerJH. The glomerular basement membrane as a barrier to albumin. Nat Rev Nephrol, 9: 470–477, 2013.
285.
SummaD, SpigaO, BerniniA, VendittiV, PrioraR, FrosaliS, MargaritisA, Di GiuseppeD, NiccolaiN, and Di SimplicioP. Protein-thiol substitution or protein dethiolation by thiol/disulfide exchange reactions: the albumin model. Proteins, 69: 369–378, 2007.
286.
TakamuraN, ShinozawaS, MaruyamaT, SuenagaA, and OtagiriM. Effects of fatty acids on serum binding between furosemide and valproic acid. Biol Pharm Bull, 21: 174–176, 1998.
287.
TaokaS, OhjaS, ShanX, KrugerWD, and BanerjeeR. Evidence for heme-mediated redox regulation of human cystathionine beta-synthase activity. J Biol Chem, 273: 25179–25184, 1998.
288.
TentenV, MenzelS, KunterU, SickingEM, van RoeyenCR, SandenSK, KaldenbachM, BoorP, FussA, UhligS, LanzmichR, WillemsenB, DijkmanH, GreplM, WildK, KrizW, SmeetsB, FloegeJ, and MoellerMJ. Albumin is recycled from the primary urine by tubular transcytosis. J Am Soc Nephrol, 241: 1966–1980, 2013.
289.
TerawakiH, YoshimuraK, HasegawaT, MatsuyamaY, NegawaT, YamadaK, MatsushimaM, NakayamaM, HosoyaT, and EraS. Oxidative stress is enhanced in correlation with renal dysfunction: examination with the redox state of albumin. Kidney Int, 66: 1988–1993, 2004.
290.
ThalSC and NeuhausW. The blood-brain barrier as a target in traumatic brain injury treatment. Arch Med Res, 45: 698–710, 2014.
291.
ThomasME, MorrisonAR, and SchreinerGF. Metabolic effects of fatty acid-bearing albumin on a proximal tubule cell line. Am J Physiol, 268: F1177–F1184, 1995.
292.
TianZ, SuttonBJ, and ZhangX. Distribution of rat neonatal Fc receptor in the principal organs of neonatal and pubertal rats. J Recept Signal Transduct Res, 34: 137–142, 2014.
293.
TietzS and EngelhardtB. Brain barriers: crosstalk between complex tight junctions and adherens junctions. J Cell Biol, 209: 493–506, 2015.
294.
TorresMJ, TurellL, BottiH, AntmannL, CarballalS, Ferrer-SuetaG, RadiR, and AlvarezB. Modulation of the reactivity of the thiol of human serum albumin and its sulfenic derivative by fatty acids. Arch Biochem Biophys, 521: 102–110, 2012.
295.
TreyerA and MüschA. Hepatocyte polarity. Compr Physiol, 3: 243–287, 2013.
296.
TurellL, RadiR, and AlvarezB. The thiol pool in human plasma: the central contribution of albumin to redox processes. Free Radic Biol Med, 65: 244–253, 2013.
297.
TyagiN, OvechkinAV, LominadzeD, MoshalKS, and TyagiSC. Mitochondrial mechanism of microvascular endothelial cells apoptosis in hyperhomocysteinemia. J Cell Biochem, 98: 1150–1162, 2006.
298.
TyagiN, SedorisKC, SteedM, OvechkinAV, MoshalKS, and TyagiSC. Mechanisms of homocysteine-induced oxidative stress. Am J Physiol Heart Circ Physiol, 289: H2649–H2656, 2005.
299.
UelandPM. Pharmacological and biochemical aspects of S-adenosylhomocysteine and S-adenosylhomocysteine hydrolase. Pharmacol Rev, 34: 223–253, 1982.
300.
UelandPM and LoscalzoJ. Homocysteine and cardiovascular risk: the perils of reductionism in a complex system. J Clin Chem, 58: 1623–1625, 2012.
301.
UelandPM, RefsumH, StablerSP, MalinowMR, AnderssonA, and AllenRH. Total homocysteine in plasma or serum: methods and clinical applications. Clin Chem, 39: 1764–1779, 1993.
302.
UlivelliM, PrioraR, Di GiuseppeD, CoppoL, SummaD, MargaritisA, FrosaliS, BartaliniS, MartiniG, CeraseA, and Di SimplicioP. Homocysteinemia control by cysteine in cerebral vascular patients after methionine loading test: evidences in physiological and pathological conditions in cerebro-vascular and multiple sclerosis patients. Amino Acids, 48: 1477–1489, 2016.
303.
UndasA, WilliamsEB, ButenasS, OrfeoT, and MannKG. Homocysteine inhibits inactivation of factor Va by activated protein C. J Biol Chem, 276: 4389–4397, 2001.
304.
UpchurchGRJr., WelchGN, FabianAJ, FreedmanJE, JohnsonJL, KeaneyJFJr., and LoscalzoJ. HomocystIine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase. J Biol Chem, 272: 17012–17017, 1997.
305.
UrquhartBL, FreemanDJ, CutlerMJ, MainraR, SpenceJD, and HouseAA. Mesna for treatment of hyperhomocysteinemia in hemodialysis patients: a placebo-controlled, double-blind, randomized trial. Clin J Am Soc Nephrol, 3: 1041–1047, 2008.
306.
UrquhartBL, FreemanDJ, SpenceJD, and HouseAA. Mesna a nonvitamin intervention to lower plasma total homocysteine concentrations: implications for assessment of the homocysteine theory of atherosclerosis. J Clin Pharmacol, 47: 991–997, 2007.
307.
UrquhartBL, HouseAA, CutlerMJ, SpenceJD, and FreemanDJ. Thiol exchange: an in vivo assay that predicts the efficacy of novel homocysteinemia lowering therapies. J Pharmacol Sci, 25: 1742–1750, 2006.
308.
van der KnaapMS and BugianiM. Leukodystrophies: a proposed classification system based on pathological changes and pathogenetic mechanisms. Acta Neuropathol, 134: 351–382, 2017.
309.
van der VusseGJ. Albumin as fatty acid transporter. Drug Metab Pharmacokinet, 24: 300–307, 2009.
310.
van HorssenJ, DijkstraCD, and de VriesHE. The extracellular matrix in multiple sclerosis pathology. J Neurochem, 103: 1293–1301, 2007.
311.
van HorssenJ, WitteME, SchreibeltG, and de VriesHE. Radical changes in multiple sclerosis pathogenesis. Biochim Biophys Acta, 1812: 141–150, 2011.
312.
VignaniR, MilanesiC, and Di SimplicioP. Disruption of cytoskeleton by methylmercury in cultured CHO cells. Toxicol In Vitro, 6: 61–70, 1992.
313.
VollsetSE, RefsumE, TverdalA, NygårdO, NordrehaugJE, TellGS, and UelandPM. Plasma total homocysteine and cardiovascular and noncardiovascular mortality: the HordalandHomocysteine. Study. Am J Clin Nutr, 74: 130–136, 2001.
314.
VorumH and HonoréB. Influence of fatty acids on the binding of warfarin and phenprocoumon to human serum albumin with relation to anticoagulant therapy. J Pharm Pharmacol, 48: 870–875, 1996.
315.
WaldDS, LawM, and MorrisJK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ, 325: 1202–1209, 2002.
316.
WaldmannTA and StroberW. Metabolism of immunoglobulins. Prog Allergy, 13: 1–110, 1969.
317.
WaldmannTA and TerryWD. Familial hypercatabolic hypoproteinemia. A disorder of endogenous catabolism of albumin and immunoglobulin. J Clin Invest, 86: 2093–2098, 1990.
318.
WangG andO K. Homocysteine stimulates the expression of monocyte chemoattractant protein-1 receptor (CCR2) in human monocytes: possible involvement of oxygen free radicals. Biochem J, 357: 233–240, 2001.
319.
WangG, SiowYL, and KarminO. Homocysteine stimulates nuclear factor kappaB activity and monocyte chemoattractant protein-1 expression in vascular smooth-muscle cells: a possible role for protein kinase C. Biochem J, 352: 817–826, 2000.
320.
WangSC and FreyPA. Binding energy in the one-electron reductive cleavage of S-adenosylmethionine in lysine 2,3-aminomutase, a radical SAM. enzyme. Biochemistry, 46: 12889–12895, 2007.
321.
WaniMA, HaynesLD, KimJ, BronsonCL, ChaudhuryC, MohantyS, WaldmannTA, RobinsonJM, and AndersonCL. Familial hypercatabolic hypoproteinemia caused by deficiency of the neonatalFc receptor, FcRn, due to a mutant beta2-microglobulin gene. Proc Natl Acad Sci U S A, 103: 5084–5089, 2006.
322.
WardES and OberRJ. Multitasking by exploitation of intracellular transport functions the many faces of FcRn. Adv Immunol, 103: 77–115, 2009.
WeissN, MillerF, CazaubonS, and CouraudPO. The blood-brain barrier in brain homeostasis and neurological diseases. Biochim Biophys Acta, 1788: 842–857, 2009.
325.
WelchGN and LoscalzoJ. Homocysteine and atherothrombosis. N Engl J Med, 338: 1042–1250, 1998.
326.
WolthersKR and ScruttonNS. Cobalamin uptake and reactivation occurs through specific protein interactions in the methionine synthase-methionine synthase reductase complex. FEBS J, 276: 1942–1951, 2009.
327.
WongAD, YeM, LevyAF, RothsteinJD, BerglesDE, and SearsonPC. The blood-brain barrier: an engineering perspective. Front Neuroeng, 6: 7, 2013.
328.
WuC, BelendaC, LerouxJC, and GauthierMA. Interplay of chemical microenvironment and redox environment on thiol-disulfide exchange kinetics. Chem Eur J, 17: 10064–10070, 2011.
329.
XiaoW and LoscalzoJ. Metabolic responses to reductive stress. Antioxid Redox Signal, 32: 1330–1347, 2020.
330.
XiaoY, HuangW, ZhangJ, PengC, XiaM, and LingW. Increased plasma S-adenosylhomocysteine-accelerated atherosclerosis is associated with epigenetic regulation of endoplasmic reticulum stress in apoE−/−mice. Arterioscler Thromb Vasc Biol, 35: 60–70, 2015a.
331.
XiaoY, SuX, HuangW, ZhangJ, PengC, HuangH, WuX, HuangH, XiaM, and LingW. Role of S-adenosylhomocysteine in cardiovascular disease and its potential epigenetic mechanism. Int J Biochem Cell Biol, 67: 158–166, 2015b.
332.
XuD, NevilleR, and FinkelT. Homocysteine accelerates endothelial cell senescence. FEBS Lett, 470: 20–24, 2000.
333.
YamadaK, GravelRA, TorayaT, and MatthewsRG. Human methionine synthase reductase is a molecular chaperone for human methionine synthase. Proc Natl Acad Sci U S A, 103: 9476–9481, 2006.
334.
YamasakiK, ChuangVT, MaruyamaT, and OtagiriM. Albumin-drug interaction and its clinical implication. Biochim Biophys Acta, 1830: 5435–5443, 2013.
335.
YangF, ZhangY, and LiangH. Interactive association of drugs binding to human serum albumin. Int J Mol Sci, 15: 3580–3595, 2014.
336.
YiP, MelnykS, PogribnaM, PogribnyIP, HineRJ, and JamesSJ. Increase in plasma homocysteine associated with parallel increases in plasma S-adenosylhomocysteine and lymphocyteDNA. hypomethylation. J Biol Chem, 275: 29318–29323, 2000.
337.
YokotaS and FahimiHD. Immunocytochemical localization of albumin in the secretory apparatus of rat liver parenchymal cells. Proc Natl Acad Sci U S A, 78: 4970–4974, 1981.
338.
YuSM-W, NissaisorakarnP, HusainI, and JimB. Proteinuric kidney diseases: a podocyte's slit diaphragm and cytoskeleton approach. Front Med (Lausanne), 5: 221, 2018.
339.
ZhangJ, YeZ-W, SinghS, TownsendDM, and TewKD. An evolving understanding of the S- glutathionylation cycle in pathways of redox regulation. Free Radic Biol Med, 120: 204–216, 2018.
340.
ZhaoX, JiangC, OlufadeR, LiuD, and EmmettN. Kidney injury molecule-1 enhances endocytosis of albumin in renal proximal tubular cells. J Cell Physiol, 231: 896–907, 2016.
341.
ZhouJ, WerstuckGH, LhotakS, de KoningABL, SoodSK, HoussainGS, MollerJ, Ritskes-HoitingaM, FalkE, DayalS, LentzSR, and AustinRC. Association of multiple cellular stress pathways with accelerated atherosclerosis in hyperhomocysteinemic apolipoprotein E-deficient mice. Circulation, 110: 207–213, 2004.
342.
ZouT, YangW, HouZ, and YangJ. Homocysteine enhances cell proliferation in vascular smooth muscle cells: role of p38 MAPK and. p47phox. Acta Biochim Biophys Sin, 42: 908–915, 2010.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
